Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TMCI Stock Forecast 2026-2027
$4.06
Current Price
$263.38M
Market Cap
Buy 1
Hold 3
Sell 1
Wall St Analyst Ratings
Distance to TMCI Price Targets
+72.4%
To High Target of $7.00
-26.1%
To Median Target of $3.00
-50.7%
To Low Target of $2.00
TMCI Price Momentum
+15.7%
1 Week Change
+46.6%
1 Month Change
-28.4%
1 Year Change
+65.7%
Year-to-Date Change
-47.8%
From 52W High of $7.78
+247.0%
From 52W Low of $1.17
📊 TOP ANALYST CALLS
Did TMCI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Treace Medical is one of their latest high-conviction picks.
Latest TMCI Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, TMCI has a neutral consensus with a median price target of $3.00 (ranging from $2.00 to $7.00). The overall analyst rating is Buy (6.4/10). Currently trading at $4.06, the median forecast implies a -26.1% downside. This outlook is supported by 1 Buy, 3 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Ben Haynor at Lake Street, projecting a 72.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TMCI Analyst Ratings
1
Buy
3
Hold
1
Sell
TMCI Price Target Range
Low
$2.00
Average
$3.00
High
$7.00
Current: $4.06
Latest TMCI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TMCI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 2, 2026 | Lake Street | Ben Haynor | Buy | Maintains | $7.00 |
| Jan 7, 2026 | Stifel | Hold | Maintains | $N/A | |
| Dec 18, 2025 | Truist Securities | Hold | Maintains | $N/A | |
| Nov 10, 2025 | Truist Securities | Hold | Reiterates | $N/A | |
| Nov 7, 2025 | UBS | Neutral | Maintains | $N/A | |
| Nov 7, 2025 | JP Morgan | Underweight | Downgrade | $N/A | |
| Nov 7, 2025 | BTIG | Neutral | Downgrade | $N/A | |
| Oct 15, 2025 | Truist Securities | Hold | Maintains | $N/A | |
| Sep 4, 2025 | Truist Securities | Hold | Maintains | $N/A | |
| Aug 8, 2025 | UBS | Neutral | Maintains | $N/A | |
| Aug 8, 2025 | Stifel | Hold | Maintains | $N/A | |
| May 9, 2025 | UBS | Neutral | Maintains | $N/A | |
| Apr 11, 2025 | Truist Securities | Hold | Maintains | $N/A | |
| Mar 13, 2025 | Truist Securities | Hold | Maintains | $N/A | |
| Mar 3, 2025 | Truist Securities | Hold | Maintains | $N/A | |
| Dec 31, 2024 | Lake Street | Buy | Initiates | $N/A | |
| Dec 18, 2024 | Truist Securities | Hold | Maintains | $N/A | |
| Nov 6, 2024 | Stifel | Hold | Maintains | $N/A | |
| Oct 14, 2024 | Truist Securities | Hold | Maintains | $N/A | |
| Aug 7, 2024 | UBS | Neutral | Maintains | $N/A |
Treace Medical Concepts, Inc. (TMCI) Competitors
The following stocks are similar to Treace Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TMCI
Treace Medical
mkt cap
263.38M
Treace Medical Concepts, Inc. (TMCI) Financial Data
Treace Medical Concepts, Inc. has a market capitalization of $263.38M with a P/E ratio of -4.4x. The company generates $207.32M in trailing twelve-month revenue with a -29.4% profit margin.
Revenue growth is -10.2% quarter-over-quarter, while maintaining an operating margin of -36.4% and return on equity of -66.9%.
Valuation Metrics
Market Cap
$263.38M
Enterprise Value
$273.40M
P/E Ratio
-4.4x
PEG Ratio
-0.4x
Price/Sales
1.2x
Growth & Margins
Revenue Growth (YoY)
-10.2%
Gross Margin
+79.3%
Operating Margin
-36.4%
Net Margin
-29.4%
EPS Growth
-10.2%
Financial Health
Cash/Price Ratio
+19.7%
Current Ratio
3.6x
Debt/Equity
92.8x
ROE
-66.9%
ROA
-17.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Treace Medical Concepts, Inc. (TMCI) Business Model
About Treace Medical Concepts, Inc.
What They Do
Develops orthopedic medical devices for bunion correction.
Business Model
Treace Medical Concepts generates revenue by selling its flagship product, the Lapiplasty 3D Bunion Correction System, to hospitals, surgeons, and healthcare providers. The company leverages a robust network of sales representatives and medical partnerships to distribute its innovative solutions, enhancing surgical techniques and patient outcomes.
Additional Information
Headquartered in Ponte Vedra, Florida, Treace Medical Concepts is committed to integrating research and technology into its product offerings, positioning itself as a key player in the medical device industry. The focus on improving recovery experiences for patients highlights the company’s dedication to enhancing healthcare quality.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
450
CEO
Mr. John T. Treace
Country
United States
IPO Year
2021
Website
www.treace.comTreace Medical Concepts, Inc. (TMCI) Latest News & Analysis
Latest News
Quick Summary
Treace Medical Concepts, Inc. (TMCI) will present at the Sidoti Small Cap Conference on June 18, 2026, at 1:45 pm ET, focusing on its innovations in bunion surgery.
Why It Matters
Treace Medical's presentation at a notable conference could signal growth potential and attract investor interest, impacting stock performance and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Johnson Fistel is investigating potential claims for investors in Treace Medical Concepts (TMCI) regarding possible losses tied to the company's executive officers under federal securities laws.
Why It Matters
The investigation into Treace Medical Concepts may signal potential legal issues or financial mismanagement, which could impact stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Treace Medical Concepts (TMCI) maintained its 2026 revenue outlook despite a first-quarter revenue decline, citing new product adoption boosting procedure volumes.
Why It Matters
Treace Medical's reaffirmed 2026 revenue outlook amid a Q1 decline suggests resilience, indicating potential for long-term growth despite short-term challenges, which may attract investor interest.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Treace Medical Concepts, Inc. (TMCI) held its Q1 2026 earnings call, discussing financial performance and future outlook. For detailed results, refer to the full transcript.
Why It Matters
Treace Medical's Q1 2026 earnings reveal performance trends, revenue growth, and operational efficiency, which can impact stock valuation and future investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) reported its financial results for Q1 2026, focusing on advancements in surgical treatments for bunions and midfoot deformities.
Why It Matters
Treace's Q1 financial results indicate its growth and performance in a niche market, potentially affecting stock performance and investor sentiment regarding future profitability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Treace Medical Concepts (TMCI) reported a quarterly loss of $0.28 per share, better than the expected loss of $0.31, but worse than a loss of $0.25 per share from the previous year.
Why It Matters
Treace Medical's smaller-than-expected loss indicates better-than-anticipated performance, which may boost investor confidence and affect stock price positively.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About TMCI Stock
What is Treace Medical Concepts, Inc.'s (TMCI) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Treace Medical Concepts, Inc. (TMCI) has a median price target of $3.00. The highest price target is $7.00 and the lowest is $2.00.
Is TMCI stock a good investment in 2026?
According to current analyst ratings, TMCI has 1 Buy ratings, 3 Hold ratings, and 1 Sell ratings. The stock is currently trading at $4.06. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TMCI stock?
Wall Street analysts predict TMCI stock could reach $3.00 in the next 12 months. This represents a -26.1% decrease from the current price of $4.06. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Treace Medical Concepts, Inc.'s business model?
Treace Medical Concepts generates revenue by selling its flagship product, the Lapiplasty 3D Bunion Correction System, to hospitals, surgeons, and healthcare providers. The company leverages a robust network of sales representatives and medical partnerships to distribute its innovative solutions, enhancing surgical techniques and patient outcomes.
What is the highest forecasted price for TMCI Treace Medical Concepts, Inc.?
The highest price target for TMCI is $7.00 from Ben Haynor at Lake Street, which represents a 72.4% increase from the current price of $4.06.
What is the lowest forecasted price for TMCI Treace Medical Concepts, Inc.?
The lowest price target for TMCI is $2.00 from at , which represents a -50.7% decrease from the current price of $4.06.
What is the overall TMCI consensus from analysts for Treace Medical Concepts, Inc.?
The overall analyst consensus for TMCI is neutral. Out of 2 Wall Street analysts, 1 rate it as Buy, 3 as Hold, and 1 as Sell, with a median price target of $3.00.
How accurate are TMCI stock price projections?
Stock price projections, including those for Treace Medical Concepts, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 14, 2026 3:24 AM UTC